Long-acting reversible contraception: A review in special populations

Pharmacotherapy

Volumn 34, Issue 1, 2014, Pages 46-59

  Prescott, Gina M ^a   Matthews, Christina M ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

Adolescents; Contraception; Contraceptive implant; Intrauterine device; Postpartum

Indexed keywords

CONTRACEPTIVE AGENT; COPPER INTRAUTERINE DEVICE; EFAVIRENZ; ESTROGEN; ETONOGESTREL; GESTAGEN; LEVONORGESTREL; LONG ACTING REVERSIBLE CONTRACEPTIVE AGENT; MEDROXYPROGESTERONE ACETATE; UNCLASSIFIED DRUG;

ABDOMINAL CRAMP; ADOLESCENT PREGNANCY; AMENORRHEA; ARTICLE; BREAST FEEDING; CD4 LYMPHOCYTE COUNT; CESAREAN SECTION; DEVICE INFECTION; DEVICE REMOVAL; DYSMENORRHEA; EMERGENCY CONTRACEPTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION; INTRAUTERINE DEVICE EXPULSION; LOW DRUG DOSE; MENORRHAGIA; MENSTRUAL IRREGULARITY; MILK PRODUCTION; NULLIPARA; PAIN; PELVIC INFLAMMATORY DISEASE; PUERPERIUM; SEXUALLY TRANSMITTED DISEASE; THROMBOPHLEBITIS; UNPLANNED PREGNANCY; UTERUS PERFORATION; VAGINAL DELIVERY; VENOUS THROMBOEMBOLISM; VIRUS SHEDDING; VIRUS TRANSMISSION;

ADOLESCENTS; CONTRACEPTION; CONTRACEPTIVE IMPLANT; INTRAUTERINE DEVICE; POSTPARTUM;

AGE FACTORS; ANIMALS; CONTRACEPTION; CONTRACEPTIVE AGENTS, FEMALE; DESOGESTREL; DRUG IMPLANTS; FEMALE; HIV INFECTIONS; HUMANS; INTRAUTERINE DEVICES, COPPER; LEVONORGESTREL; PREGNANCY; RISK FACTORS; SEXUALLY TRANSMITTED DISEASES;

EID: 84898040576     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1002/phar.1358     Document Type: Article

References (69)

1. Trussell J, Henry N, Hassan F, Prezioso A, Law A, Filonenko A. Burden of unintended pregnancy in the United States: potential savings with increased use of long-acting reversible contraception. Contraception 2013, 87(2): 154-161.
2. Jones J, Mosher W, Daniels K. Current contraceptive use in the United States, 2006-2010, and changes in patterns of use since 1995. National Health Statistics Reports 2012; 60: 26.
3. Finer LB, Zolna MR. Unintended pregnancy in the United States: incidence and disparities, 2006. Contraception 2011;5: 478-85.
4. U.S. Department of Health and Human Services. Office of Disease Prevention and Health Promotion. Healthy People 2020. Available from http://www.healthypeople.gov/2020/topicsobjectives2020/objectiveslist.aspx? topicId=13. Accessed September 20, 2012.
5. Health Resources and Services Administration. Women's preventive services: required heath plan coverage guidelines, Available from http://www.hrsa.gov/womensguidelines/. Accessed March 27, 2013.
6. Hatcher RA, Trussell J, Nelson AL, Cates W, Kowal D, Policar MS. Contraceptive technology: Twentieth Revised Edition. New York: Ardent Media, Inc.; 2011.
7. American College of Obsterticians and Gynecologists. ACOG Practice Bulletin No. 121: long-acting reversible contraception: implants and intrauterine devices. Obstet Gynecol 2011;1: 184-96.
8. Zieman M, Hatcher RA. Managing contraception on the go. Tiger, GA: Bridging the Gap Foundation; 2012.
9. Secura GM, Allsworth JE, Madden T, Mullersman JL, Peipert JF. The Contraceptive CHOICE Project: reducing barriers to long-acting reversible contraception. Am J Obstet Gynecol 2010;2: 115 e1-7.
10. U.S. medical eligibility criteria for contraceptive use, 2010. MMWR Recomm Rep 2010;RR-4: 1-86.
11. World Health Organization. Medical eligibility criteria for contraceptive use: a WHO family planning cornerstone. Geneva: World Health Organization, 2010.
12. Wright RL, Frost CJ, Turok DK. A qualitative exploration of emergency contraception users' willingness to select the copper IUD. Contraception 2012;1: 32-5.
13. Teva Women's Health Inc. ParaGard T 380A intrauterine copper contraceptive package insert. Sellersville, PA: Teva Pharmaceuticals USA Inc.
14. Trussell J. Contraceptive failure in the United States. Contraception 2011;83(5): 397-404.
15. RED BOOK Online. Available from http://www.micromedexsolutions. com. Accessed May 20, 2013.
16. U.S. Food and Drug Administration. FDA approves additional use for IUD Mirena to treat heavy menstrual bleeding in IUD users. Available from http://www.fda.gov/News Events/Newsroom/PressAnnouncements/ucm184747.htm. Accessed October 13, 2009.
17. Washington University School of Medicine. Levonorgestrel Intrauterine System for Emergency Contraception (LIFE). In: ClinicalTrials.gov. Bethesda, MD: National Library of Medicine. Available from http://clinicaltrials.gov/show/ NCT015 39720 NLM Identifier: NCT01539720. Accessed March 29, 2013.
18. Bayer HealthCare Pharmaceuticals Inc. Mirena (levenorgestrel- releasing intrauterine system) package insert. Wayne, NJ: Bayer HealthCare Pharmaceuticals Inc., 2009.
19. Sivin I, el Mahgoub S, McCarthy T, et al. Long-term contraception with the levonorgestrel 20 μg/day (LNg 20) and the copper T 380Ag intrauterine devices: a five-year randomized study. Contraception 1990;4: 361-78.
20. Bayer HealthCare Pharmaceuticals Inc. SKYLA (levonorgestrel- releasing intrauterine system) package insert. Wayne, NJ: Bayer HealthCare Pharmaceuticals Inc., 2013.
21. Gemzell-Danielsson K, Schellschmidt I, Apter D. A randomized, phase II study describing the efficacy, bleeding profile, and safety of two low-dose levonorgestrel-releasing intrauterine contraceptive systems and Mirena. Fertil Steril 2012;3: 616-22 e1-3.
22. Merck & Co. Inc. Nexplanon (etonogestrel subdermal implant) package insert. Whitehouse Station, NJ: Merck & Co. Inc., 2012.
23. Xu H, Wade JA, Peipert JF, Zhao Q, Madden T, Secura GM. Contraceptive failure rates of etonogestrel subdermal implants in overweight and obese women. Obstet Gynecol 2012;1: 21-6.
24. Peipert JF, Madden T, Allsworth JE, Secura GM. Preventing unintended pregnancies by providing no-cost contraception. Obstet Gynecol 2012;6: 1291-7.
25. Hamilton BE, Ventura SJ. Birth rates for U.S. teenagers reach historic lows for all age and ethnic groups. NCHS Data Brief 2012;89: 1-8.
26. Winner B, Peipert JF, Zhao Q, et al. Effectiveness of long-acting reversible contraception. N Engl J Med 2012;21: 1998-2007.
27. Peipert JF, Zhao Q, Allsworth JE, et al. Continuation and satisfaction of reversible contraception. Obstet Gynecol 2011;5: 1105-13.
28. Centers for Disease Control and Prevention. Update to CDC's U.S. Medical eligibility criteria for contraceptive use, 2010: revised recommendations for the use of contraceptive methods during the postpartum period. MMWR Morb Mortal Wkly Rep 2011;26: 878-83.
29. American College of Obsterticians and Gynecologists. Breastfeeding: maternal and infant aspects. Special report from ACOG. ACOG Clin Rev 2007;1: 1S-16S.
30. Kapp N, Curtis KM. Intrauterine device insertion during the postpartum period: a systematic review. Contraception 2009;4: 327-36.
31. Brenner PF. A clinical trial of the Delta-T intrauterine device: immediate postpartum insertion. Contraception 1983;2: 135-47.
32. Mishell DR Jr, Roy S. Copper intrauterine contraceptive device event rates following insertion 4 to 8 weeks post partum. Am J Obstet Gynecol 1982;1: 29-35.
33. Levi E, Cantillo E, Ades V, Banks E, Murthy A. Immediate postplacental IUD insertion at cesarean delivery: a prospective cohort study. Contraception 2012;2: 102-5.
34. Chen BA, Reeves MF, Hayes JL, Hohmann HL, Perriera LK, Creinin MD. Postplacental or delayed insertion of the levonorgestrel intrauterine device after vaginal delivery: a randomized controlled trial. Obstet Gynecol 2010;5: 1079-87.
35. Hayes JL, Cwiak C, Goedken P, Zieman M. A pilot clinical trial of ultrasound-guided postplacental insertion of a levonorgestrel intrauterine device. Contraception 2007;4: 292-6.
36. Célen Ś, Móróy P, Sucak A, Aktulay A, Danisman N. Clinical outcomes of early postplacental insertion of intrauterine contraceptive devices. Contraception 2004;4: 279-82.
37. Chen BA, Reeves MF, Creinin MD, Schwarz EB. Postplacental or delayed levonorgestrel intrauterine device insertion and breast-feeding duration. Contraception 2011;5: 499-504.
38. Shaamash AH, Sayed GH, Hussien MM, Shaaban MM. A comparative study of the levonorgestrel-releasing intrauterine system Mirena® versus the Copper T380A intrauterine device during lactation: breast-feeding performance, infant growth and infant development. Contraception 2005;5: 346-51.
39. Brito MB, Ferriani RA, Quintana SM, Yazlle MEHD, Silva de Sá MF, Vieira CS. Safety of the etonogestrel-releasing implant during the immediate postpartum period: a pilot study. Contraception 2009;6: 519-26.
40. Reinprayoon D, Taneepanichskul S, Bunyavejchevin S, et al. Effects of the etonogestrel-releasing contraceptive implant (Implanon ®) on parameters of breastfeeding compared to those of an intrauterine device. Contraception 2000;5: 239-46.
41. American College of Obstetricians and Gynecologists. Committee opinion no. 539: adolescents long-acting reversible contraception: implants intrauterine devices. Obstet Gynecol 2012;4: 983-8.
42. Schelar E, Franzetta K, Manlove J. Repeat teen childbearing: differences across states by race and ethnicity. Child Trends Research Brief 2007.
43. Pazol K, Creanga AA, Zane SB, Burley KD, Jamieson DJ. Abortion surveillance-United States, 2009. MMWR Surveil Summ 2012;8: 1-44.
44. Mestad R, Secura G, Allsworth JE, Madden T, Zhao Q, Peipert JF. Acceptance of long-acting reversible contraceptive methods by adolescent participants in the Contraceptive CHOICE Project. Contraception 2011;5: 493-8.
45. Spies EL, Askelson NM, Gelman E, Losch M. Young women's knowledge, attitudes, and behaviors related to long-acting reversible contraceptives. Women's Health Issues 2010;6: 394-9.
46. Rosenstock JR, Peipert JF, Madden T, Zhao Q, Secura GM. Continuation of reversible contraception in teenagers and young women. Obstet Gynecol 2012;6: 1298-305.
47. Alton TM, Brock GN, Yang D, Wilking DA, Hertweck SP, Loveless MB. Retrospective review of intrauterine device in adolescent and young women. J Pediatr Adolesc Gynecol 2012;3: 195-200.
48. Office of Population Affairs. Title X family planning. Available from http://www.hhs.gov/opa/title-x-family-planning/. Accessed May 21, 2013.
49. Bayer LL, Jensen JT, Li H, Nichols MD, Bednarek PH. Adolescent experience with intrauterine device insertion and use: a retrospective cohort study. Contraception 2012;5: 443-51.
50. Lewis LN, Doherty DA, Hickey M, Skinner SR. Implanon as a contraceptive choice for teenage mothers: a comparison of contraceptive choices, acceptability and repeat pregnancy. Contraception 2010;5: 421-6.
51. Grimes DA. Intrauterine device and upper-genital-tract infection. Lancet 2000;9234: 1013-9.
52. Mohllajee AP, Curtis KM, Peterson HB. Does insertion and use of an intrauterine device increase the risk of pelvic inflammatory disease among women with sexually transmitted infection? A systematic review. Contraception 2006;2: 145-53.
53. Farley TM, Rosenberg MJ, Rowe PJ, Chen JH, Meirik O. Intrauterine devices and pelvic inflammatory disease: an international perspective. Lancet 1992;8796: 785-8.
54. Toivonen J. Intrauterine contraceptive device and pelvic inflammatory disease. Ann Med 1993;2: 171-3.
55. Sufrin CB, Postlethwaite D, Armstrong MA, Merchant M, Wendt JM, Steinauer JE. Neisseria gonorrhea and Chlamydia trachomatis screening at intrauterine device insertion and pelvic inflammatory disease. Obstet Gynecol 2012;6: 1314-21.
56. Morrison CS, Murphy L, Kwok C, Weiner DH. Identifying appropriate IUD candidates in areas with high prevalence of sexually transmitted infections. Contraception 2007;3: 185-92.
57. Centers for Disease Control and Prevention. Estimated HIV incidence in the United States, 2007-2010. HIV surveillance supplemental report 2012 2012;No. 4.
58. Centers for Disease Control and Prevention. Update to CDC's U.S. Medical Eligibility Criteria for Contraceptive Use, 2010: revised recommendations for the use of hormonal contraception among women at high risk for HIV infection or infected with HIV. MMWR Morb Mortal Wkly Rep 2012;24: 449-52.
59. American College of Obsterticians and Gynecologists. ACOG Practice Bulletin No. 117: Gynecologic care for women with human immunodeficiency virus. Obstet Gynecol 2010;6: 1492-509.
60. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1- infected adults and adolescents. 2013. "Electronic Article"
61. Sun M, Peipert JF, Zhao Q, et al. Trends in contraceptive use among women with human immunodeficiency virus. Obstet Gynecol 2012;4: 783-90.
62. Curtis KM, Nanda K, Kapp N. Safety of hormonal and intrauterine methods of contraception for women with HIV/AIDS: a systematic review. AIDS 2009;23:S55-67.
63. Heikinheimo O, Lehtovirta P, Suni J, Paavonen J. The levonorgestrel- releasing intrauterine system (LNG-IUS) in HIVinfected women-effects on bleeding patterns, ovarian function and genital shedding of HIV. Hum Reprod 2006;11: 2857-61.
64. Lehtovirta P, Paavonen J, Heikinheimo O. Experience with the levonorgestrel-releasing intrauterine system among HIVinfected women. Contraception 2007;1: 37-9.
65. Heikinheimo O, Lehtovirta P, Aho I, Ristola M, Paavonen J. The levonorgestrel-releasing intrauterine system in human immunodeficiency virus-infected women: a 5-year follow-up study. Am J Obstet Gynecol 2011;2: 126.e1-26.e4.
66. Leticee N, Viard JP, Yamgnane A, Karmochkine M, Benachi A. Contraceptive failure of etonogestrel implant in patients treated with antiretrovirals including efavirenz. Contraception 2012;4: 425-7.
67. Matiluko AA, Soundararjan L, Hogston P. Early contraceptive failure of Implanon in an HIV-seropositive patient on triple antiretroviral therapy with zidovudine, lamivudine and efavirenz. J Fam Plann Reprod Health Care 2007;4: 277-8.
68. McCarty EJ, Keane H, Quinn K, Quah S. Implanon(R) failure in an HIV-positive woman on antiretroviral therapy resulting in two ectopic pregnancies. Int J STD AIDS 2011;7: 413-4.
69. Bristol-Meyers Squibb Company. Sustiva (efavirenz oral capsule, tablets) package insert. Princeton, NJ: Bristol-Meyers Squibb Company, 2013.